Roche Holding (RHHBY) Price/OCF Ratio: History & Chart

Roche Holding AG(RHHBY)

Drug Manufacturers - General · Basel, BS

$56.39-0.50 (-0.88%)

Delayed quote: Aug 27, 2026, 4:00 PM EDT

About Roche Holding AG

Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international presence, with key operations located in countries such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium. Its pharmaceutical division is dedicated to creating and supplying a diverse array of therapeutic remedies. These target a broad spectrum of medical fields, including oncology, neuroscience, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments. The comprehensive product line further extends to treatments for specific conditions like infectious diseases, anemia, various dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation-related needs. Within its diagnostics segment, Roche develops and markets a wide variety of laboratory-based tests designed to identify and monitor numerous illnesses. These include, but are not limited to, cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. Additionally, the company is a provider of essential diagnostic instruments and reagents. Established in 1896, Roche Holding AG maintains its corporate headquarters in Basel, Switzerland.

Basel, BS

103,249 employees

www.roche.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Thomas Schinecker

View full financials

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Roche Holding AG (RHHBY)	$359.46B	N/A	N/A	N/A	N/A
UnitedHealth Group Incorporated (UNH)vs ›	$358.76B	13.25	13.92	20.82	19.65
Merck & Co., Inc. (MRK)vs ›	$369.34B	18.95	15.55	15.97	15.64
AbbVie Inc. (ABBV)vs ›	$455.87B	23.87	19.93	17.12	14.67
AstraZeneca PLC (AZN)vs ›	$255.15B	18.78	19.47	19.79	21.92
Amgen Inc. (AMGN)vs ›	$235.85B	19.20	16.19	17.22	15.97
Thermo Fisher Scientific Inc. (TMO)vs ›	$234.38B	25.96	25.27	24.16	24.21
Novo Nordisk A/S (NVO)vs ›	$205.42B	10.19	11.51	22.99	24.77
Abbott Laboratories (ABT)vs ›	$193.04B	20.08	21.02	24.16	22.45
Gilead Sciences, Inc. (GILD)vs ›	$184.82B	13.58	15.90	13.29	11.68

NAME

MARKET CAP

PRICE/OCF RATIO

TTM

Roche Holding AG (RHHBY)

$359.46B

N/A

UnitedHealth Group Incorporated (UNH)vs ›

$358.76B

13.25

13.92

20.82

19.65

Merck & Co., Inc. (MRK)vs ›

$369.34B

18.95

15.55

15.97

15.64

AbbVie Inc. (ABBV)vs ›

$455.87B

23.87

19.93

17.12

14.67

AstraZeneca PLC (AZN)vs ›

$255.15B

18.78

19.47

19.79

21.92

Amgen Inc. (AMGN)vs ›

$235.85B

19.20

16.19

17.22

15.97

Thermo Fisher Scientific Inc. (TMO)vs ›

$234.38B

25.96

25.27

24.16

24.21

Novo Nordisk A/S (NVO)vs ›

$205.42B

10.19

11.51

22.99

24.77

Abbott Laboratories (ABT)vs ›

$193.04B

20.08

21.02

24.16

22.45

Gilead Sciences, Inc. (GILD)vs ›

$184.82B

13.58

15.90

13.29

11.68

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Price/OCF Ratio: N/A

RHHBY Price/OCF Ratio Metrics

RHHBY Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics